Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development
TAMPA, Fla., Oct. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Intezyne Technologies, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it closed an oversubscribed $10M Series A Preferred round lead ... Biopharmaceuticals, Oncology, Venture Capital, Personnel Intezyne Technologies, Cancer Resistance Pathway
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Marketing | Pharmaceuticals | Venture Capital